Brokerages expect that Antares Pharma Inc (NASDAQ:ATRS) will announce earnings per share (EPS) of ($0.02) for the current quarter, according to Zacks. Four analysts have made estimates for Antares Pharma’s earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at ($0.01). Antares Pharma posted earnings of ($0.01) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 100%. The firm is scheduled to issue its next earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Antares Pharma will report full year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.10) to ($0.05). For the next year, analysts expect that the company will report earnings of $0.16 per share, with EPS estimates ranging from $0.00 to $0.28. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. The firm had revenue of $28.43 million during the quarter, compared to analysts’ expectations of $21.66 million.

Separately, BidaskClub cut Antares Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $5.04.

ATRS traded up $0.12 on Friday, hitting $3.48. 902,768 shares of the company were exchanged, compared to its average volume of 1,006,463. Antares Pharma has a twelve month low of $2.53 and a twelve month high of $3.96. The company has a market cap of $567.46 million, a price-to-earnings ratio of -87.00 and a beta of 0.90. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01. The firm has a 50-day moving average price of $3.23 and a two-hundred day moving average price of $3.11.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC lifted its holdings in Antares Pharma by 6.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 59,943 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 3,800 shares during the last quarter. Prudential Financial Inc. lifted its holdings in Antares Pharma by 33.8% during the 2nd quarter. Prudential Financial Inc. now owns 18,530 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 4,680 shares during the last quarter. Alpine Woods Capital Investors LLC lifted its holdings in Antares Pharma by 60.0% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 16,000 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 6,000 shares during the last quarter. Corrado Advisors LLC purchased a new stake in Antares Pharma during the 2nd quarter worth about $26,000. Finally, JPMorgan Chase & Co. lifted its holdings in Antares Pharma by 26.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 44,424 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 9,203 shares during the last quarter. 38.76% of the stock is owned by institutional investors.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Read More: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.